Fibrolamellar carcinoma: A review with focus on genetics and comparison to other malignant primary liver tumors

Seminars in Liver Disease

Volumn 31, Issue 1, 2011, Pages 61-70

  Ward, Stephen C ^a   Waxman, Samuel ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cholangiocarcinoma; comparative genomic hybridization; Fibrolamellar carcinoma; hepatoblastoma; hepatocellular carcinoma

Indexed keywords

CD133 ANTIGEN; CISPLATIN; COLLAGEN FIBER; EPITHELIAL MEMBRANE ANTIGEN; FLUOROURACIL; HERMES ANTIGEN; MITOCHONDRIAL DNA; SORAFENIB;

ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; COMPARATIVE GENOMIC HYBRIDIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; EPIGENETICS; FIBROLAMELLAR CARCINOMA; GENETIC POLYMORPHISM; GENETICS; HEPATOBLASTOMA; HETEROZYGOSITY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TUMOR; MALIGNANT NEOPLASTIC DISEASE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; STEM CELL; TUMOR CELL; ULTRASTRUCTURE ANALYSIS AND ELECTRON MICROSCOPY;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; CHILD; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79951918659     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1272835     Document Type: Article

References (83)

1. Edmondson H A. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 1956 91 2 168-186
2. Craig J R., Peters R L., Edmondson H A., Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive cli (Pubitemid 10085954)
3. Berman M M., Libbey N P., Foster J H. Hepatocellular carcinoma. Polygonal cell type with fibrous stromaan atypical variant with a favorable prognosis. Cancer 1980 46 6 1448-1455 (Pubitemid 11253534)
4. Berman M A., Burnham J A., Sheahan D G. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 1988 19 7 784-794
5. El-Serag H B., Davila J A. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004 39 3 798-803 (Pubitemid 38337660)
6. Stipa F, Yoon S S., Liau K H. et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006 106 6 1331-1338 (Pubitemid 43363911)
7. Lazaridis K N., Gores G J. Cholangiocarcinoma. Gastroenterology 2005 128 6 1655-1667 (Pubitemid 40692558)
8. Meyers R L. Tumors of the liver in children. Surg Oncol 2007 16 3 195-203 (Pubitemid 350086944)
9. Ward S C., Thung S N., Lim K H. et al. Hepatic progenitor cells in liver cancers from Asian children. Liver Int 2010 30 1 102-111
10. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 2007 14 3 217-223 (Pubitemid 46659192)
11. Waxman S, Gilbert H S. A tumor-related vitamin B12 binding protein in adolescent hepatoma. N Engl J Med 1973 289 20 1053-1056
12. Wasman S, Gilbert H S. Characteristics of a novel serum vitamin-B12-binding protein associated with hepatocellular carcinoma. Br J Haematol 1974 27 2 229-239
13. Burger R L., Waxman S, Gilbert H S., Mehlman C S., Allen R H. Isolation and characterization of a novel vitamin B12-binding protein associated with hepatocellular carcinoma. J Clin Invest 1975 56 5 1262-1270
14. Waxman S, Liu C K., Schreiber C, Helson L. The clinical and physiological implications of hepatoma B12-binding proteins. Cancer Res 1977 37 6 1908-1914 (Pubitemid 8095210)
15. Ashwell G, Morell A G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 1974 41 0 99-128
16. Paradinas F J., Melia W M., Wilkinson M L. et al. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed) 1982 285 6345 840-842 (Pubitemid 12067725)
17. van Tonder S, Kew M C., Hodkinson J, Metz J, Fernandes-Costa F. Serum vitamin B12 binders in South African blacks with hepatocellular carcinoma. Cancer 1985 56 4 789-792 (Pubitemid 15228270)
18. Wheeler K, Pritchard J, Luck W, Rossiter M. Transcobalamin I as a marker for fibrolamellar hepatoma. Med Pediatr Oncol 1986 14 4 227-229
19. Kanai T, Takabayashi T, Kawano Y, Kuramochi S, Miyazawa N. A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity in a young Japanese female. Jpn J Clin Oncol 2004 34 6 346-351 (Pubitemid 43115317)
20. Collier N A., Weinbren K, Bloom S R., Lee Y C., Hodgson H J., Blumgart L H. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet 1984 1 8376 538-540 (Pubitemid 14197213)
21. Ward S C., Huang J, Tickoo S K., Thung S N., Ladanyi M, Klimstra D S. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 2010 23 9 1180-1190
22. Ichikawa T, Federle M P., Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology 1999 213 2 352-361 (Pubitemid 29510577)
23. Kim T, Hori M, Onishi H. Liver masses with central or eccentric scar. Semin Ultrasound CT MR 2009 30 5 418-425
24. Vecchio F M., Fabiano A, Ghirlanda G, Manna R, Massi G. Fibrolamellar carcinoma of the liver: the malignant counterpart of focal nodular hyperplasia with oncocytic change. Am J Clin Pathol 1984 81 4 521-526 (Pubitemid 14174586)
25. Terracciano L M., Tornillo L, Avoledo P, Von Schweinitz D, Khne T, Bruder E. Fibrolamellar hepatocellular carcinoma occurring 5 years after hepatocellular adenoma in a 14-year-old girl: a case report with comparative genomic hybridization analysis. Arch Pathol Lab Med 2004 128 2 222-226 (Pubitemid 38155672)
26. Farhi D C., Shikes R H., Silverberg S G. Ultrastructure of fibrolamellar oncocytic hepatoma. Cancer 1982 50 4 702-709 (Pubitemid 12052718)
27. Xu Y H., Peters R L. Mitochondrial abnormalities in hepatocytes adjacent to fibrolamellar hepatocellular carcinoma. J Tongji Med Univ 1986 6 1 26-30
28. Haratake J, Scheuer P J. An immunohistochemical and ultrastructural study of the sinusoids of hepatocellular carcinoma. Cancer 1990 65 9 1985-1993 (Pubitemid 20147638)
29. Shafizadeh N, Ferrell L D., Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008 21 8 1011-1018
30. Abdul-Al H M., Wang G, Makhlouf H R., Goodman Z D. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma. Int J Surg Pathol 2010 18 5 313-318
31. Van Eyken P, Sciot R, Brock P, Casteels-Van Daele M, Ramaekers F C., Desmet V J. Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology 1990 17 2 101-107 (Pubitemid 20258632)
32. Grnicka B, Ziarkiewicz-Wrblewska B, Wrblewski T et al. Carcinoma, a fibrolamellar variantimmunohistochemical analysis of 4 cases. Hepatogastroenterology 2005 52 62 519-523
33. Klein W M., Molmenti E P., Colombani P M. et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol 2005 124 512-518 (Pubitemid 41395631)
34. Durnez A, Verslype C, Nevens F et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006 49 2 138-151 (Pubitemid 44079697)
35. Yang X R., Xu Y, Shi G M. et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 2008 14 12 3850-3859
36. Zhuang P Y., Zhang J B., Zhu X D. et al. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer 2008 112 12 2740-2748
37. Trzpis M, McLaughlin P M., de Leij L M., Harmsen M C. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007 171 2 386-395 (Pubitemid 47344671)
38. Yamashita T, Forgues M, Wang W et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008 68 5 1451-1461 (Pubitemid 351346853)
39. Zenali M J., Tan D, Li W, Dhingra S, Brown R E. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. Ann Clin Lab Sci 2010 40 2 126-134
40. Buckley A F., Burgart L J., Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol 2006 37 4 410-414
41. Orsatti G, Hytiroglou P, Thung S N., Ishak K G., Paronetto F. Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. Liver 1997 17 3 152-156 (Pubitemid 27363867)
42. Komiya T, Tanigawa Y, Hirohashi S. Cloning of the gene gob-4, which is expressed in intestinal goblet cells in mice. Biochim Biophys Acta 1999 1444 3 434-438 (Pubitemid 29147317)
43. Vivekanandan P, Micchelli S T., Torbenson M. Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. Hum Pathol 2009 40 3 293-299
44. Li W, Tan D, Zenali M J., Brown R E. Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol 2010 3 3 238-243
45. Ding S F., Delhanty J D., Bowles L, Dooley J S., Wood C B., Habib N A. Infrequent chromosome allele loss in fibrolamellar carcinoma. Br J Cancer 1993 67 2 244-246 (Pubitemid 23049544)
46. Ding S F., Habib N A., Dooley J, Wood C, Bowles L, Delhanty J D. Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis. Br J Cancer 1991 64 6 1083-1087
47. Orsatti G, Greenberg P D., Rolfes D B., Ishak K G., Paronetto F. DNA ploidy of fibrolamellar hepatocellular carcinoma by image analysis. Hum Pathol 1994 25 9 936-939 (Pubitemid 24292412)
48. Lowichik A, Schneider N R., Tonk V, Ansari M Q., Timmons C F. Report of a complex karyotype in recurrent metastatic fibrolamellar hepatocellular carcinoma and a review of hepatocellular carcinoma cytogenetics. Cancer Genet Cytogenet 1996 88 2 170-174 (Pubitemid 26196299)
49. Hany M A., Betts D R., Schmugge M et al. A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. Med Pediatr Oncol 1997 28 2 136-138 (Pubitemid 27034289)
50. Moinzadeh P, Breuhahn K, Sttzer H, Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological graderesults of an explorative CGH meta-analysis. Br J Cancer 2005 92 5 935-941 (Pubitemid 40462642)
51. Marchio A, Pineau P, Meddeb M et al. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene 2000 19 33 3733-3738 (Pubitemid 30621178)
52. Wilkens L, Bredt M, Flemming P, Kubicka S, Klempnauer J, Kreipe H. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. Am J Clin Pathol 2000 114 6 867-874 (Pubitemid 33051886)
53. Kakar S, Chen X, Ho C et al. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Mod Pathol 2009 22 1 134-141
54. Terracciano L, Tornillo L. Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization. Pathologica 2003 95 2 71-82 (Pubitemid 40340315)
55. Koo S H., Ihm C H., Kwon K C., Park J W., Kim J M., Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet 2001 130 1 22-28 (Pubitemid 32982127)
56. Wong N, Li L, Tsang K, Lai P B., To K F., Johnson P J. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002 37 5 633-639 (Pubitemid 35305544)
57. Lee J Y., Park Y N., Uhm K O., Park S Y., Park S H. Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization. J Korean Med Sci 2004 19 5 682-687
58. Uhm K O., Park Y N., Lee J Y., Yoon D S., Park S H. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet 2005 157 1 37-41
59. Homayounfar K, Gunawan B, Cameron S et al. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol 2009 40 6 834-842
60. Steenman M, Tomlinson G, Westerveld A, Mannens M. Comparative genomic hybridization analysis of hepatoblastomas: additional evidence for a genetic link with Wilms tumor and rhabdomyosarcoma. Cytogenet Cell Genet 1999 86 2 157-161 (Pubitemid 29488311)
61. Hu J, Wills M, Baker B A., Perlman E J. Comparative genomic hybridization analysis of hepatoblastomas. Genes Chromosomes Cancer 2000 27 2 196-201 (Pubitemid 30030319)
62. Weber R G., Pietsch T, von Schweinitz D, Lichter P. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 2000 157 2 571-578 (Pubitemid 30627562)
63. Gray S G., Kytl S, Matsunaga T, Larsson C, Ekstrm T J. Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomas. Br J Cancer 2000 83 8 1020-1025
64. Adesina A M., Nguyen Y, Guanaratne P et al. FOXG1 is overexpressed in hepatoblastoma. Hum Pathol 2007 38 3 400-409 (Pubitemid 46227532)
65. Weber R G., Bostrm J, Wolter M et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997 94 26 14719-14724 (Pubitemid 28041440)
66. Kannangai R, Vivekanandan P, Martinez-Murillo F, Choti M, Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 2007 38 4 639-644 (Pubitemid 46399897)
67. Kaposi-Novak P, Libbrecht L, Woo H G. et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009 69 7 2775-2782
68. Duff E K., Clarke A R. Smad4 (DPC4)a potent tumour suppressor? Br J Cancer 1998 78 12 1615-1619 (Pubitemid 28550047)
69. Kang Y K., Kim W H., Jang J J. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 2002 33 9 877-883
70. Torbenson M, Marinopoulos S, Dang D T. et al. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling. Hum Pathol 2002 33 9 871-876
71. Poon T C., Wong N, Lai P B., Rattray M, Johnson P J., Sung J J. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 2006 131 4 1262-1270 (Pubitemid 44515104)
72. Vivekanandan P, Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol 2008 21 6 670-675 (Pubitemid 351744831)
73. Sandhu D S., Shire A M., Roberts L R. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int 2008 28 1 12-27
74. Honda S, Haruta M, Sugawara W et al. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer 2008 123 5 1117-1125
75. Vivekanandan P, Daniel H, Yeh M M., Torbenson M. Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas. Mod Pathol 2010 23 6 790-798
76. Katzenstein H M., Krailo M D., Malogolowkin M H. et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003 97 8 2006-2012 (Pubitemid 36397279)
77. Kakar S, Burgart L J., Batts K P., Garcia J, Jain D, Ferrell L D. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005 18 11 1417-1423 (Pubitemid 41509395)
78. Epstein B E., Pajak T F., Haulk T L., Herpst J M., Order S E., Abrams R A. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol 1999 22 1 22-28 (Pubitemid 30261584)
79. Fong Y, Sun R L., Jarnagin W, Blumgart L H. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999 229 6 790-799, discussion 799-800
80. Shaib Y, El-Serag H B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004 24 2 115-125 (Pubitemid 38738341)
81. Schnater J M., Aronson D C., Plaschkes J et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002 94 4 1111-1120 (Pubitemid 34150867)
82. Maniaci V, Davidson B R., Rolles K et al. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol 2009 35 6 617-621
83. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390